Anti-Mouse TRAIL R2
| Code | Size | Price |
|---|
| LEI-T474-25ug | 25 ug | £375.00 |
Quantity:
| LEI-T474-100ug | 100 ug | £671.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Neutralisation
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Antigen Affinity Purified
Format:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.4 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Formulation:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.4 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Immunogen:
NS0-Derived Recombinant Mouse TRAIL Receptor 2 Extracellular Domain
Long Description:
Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2 TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.3
NCBI Gene:
21933
Target:
TRAIL R2
References
1. Yoo, NJ. et al. (2001) Oncogene 20: 399
2. Eberle, J. et al. (2005) J Investigative Dermatol. 125: 1010
3. Rimm, D. et al. (2005) Clin Cancer Research 11
Related Products
| Product Name | Product Code | Supplier | Anti-Mouse CD262 (TRAIL R2) - Purified Functional Grade | LEI-C2424 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Mouse CD262 (TRAIL R2) - Biotin | LEI-C2426 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse CD262 (TRAIL R2) - PE | LEI-C2428 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Mouse TRAIL R2 | LEI-T406 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human TRAIL R2 | LEI-T451 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human TRAIL R2/DR5/TNFRSF10B | LEI-T471 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human TRAIL R2 - Biotin | LEI-T497 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse TRAIL R2 - Biotin | LEI-T501 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||